165 related articles for article (PubMed ID: 14694167)
1. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial.
Roger SD; McMahon LP; Clarkson A; Disney A; Harris D; Hawley C; Healy H; Kerr P; Lynn K; Parnham A; Pascoe R; Voss D; Walker R; Levin A
J Am Soc Nephrol; 2004 Jan; 15(1):148-56. PubMed ID: 14694167
[TBL] [Abstract][Full Text] [Related]
2. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
[TBL] [Abstract][Full Text] [Related]
3. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD.
Levin A; Djurdjev O; Thompson C; Barrett B; Ethier J; Carlisle E; Barre P; Magner P; Muirhead N; Tobe S; Tam P; Wadgymar JA; Kappel J; Holland D; Pichette V; Shoker A; Soltys G; Verrelli M; Singer J
Am J Kidney Dis; 2005 Nov; 46(5):799-811. PubMed ID: 16253719
[TBL] [Abstract][Full Text] [Related]
4. Italian randomized trial of hemoglobin maintenance to prevent or delay left ventricular hypertrophy in chronic kidney disease.
Cianciaruso B; Ravani P; Barrett BJ; Levin A;
J Nephrol; 2008; 21(6):861-70. PubMed ID: 19034870
[TBL] [Abstract][Full Text] [Related]
5. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia.
Thanakitcharu P; Siriwiwatanakul N
J Med Assoc Thai; 2007 Dec; 90(12):2574-86. PubMed ID: 18386706
[TBL] [Abstract][Full Text] [Related]
6. [Diastolic dysfunction in different types of left ventricular hypertrophy in patients with end-stage renal failure: impact of long-term erythropoietin therapy].
Dzgoeva FU; Gatagonova TM; Kadzaeva ZK; Khamitsaeva OV; Kochisova ZKh; Dzueva AT; Bazaeva BG; Bestaeva TL
Ter Arkh; 2013; 85(6):44-50. PubMed ID: 23866598
[TBL] [Abstract][Full Text] [Related]
7. [Improvement of left ventricular hypertrophy by anemic-correcting erythropoietin therapy in chronic renal insufficiency].
Jiang JP; Hou FF; Gao LZ; Pan YB; Yang NS; Chen W; Shu GY; Chen YM; Chen J; Peng WH; Wu JP; Yang ZM
Zhonghua Nei Ke Za Zhi; 2005 Jan; 44(1):25-9. PubMed ID: 15769393
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
10. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial.
Macdougall IC; Temple RM; Kwan JT
Nephrol Dial Transplant; 2007 Mar; 22(3):784-93. PubMed ID: 16968726
[TBL] [Abstract][Full Text] [Related]
11. Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial).
Imai E; Maruyama S; Nangaku M; Hirakata H; Hayashi T; Narita I; Kono H; Nakatani E; Morita S; Tsubakihara Y; Akizawa T
Clin Exp Nephrol; 2016 Feb; 20(1):71-6. PubMed ID: 26081567
[TBL] [Abstract][Full Text] [Related]
12. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
13. [Frequency of anaemia and indications for treatment with epoetin in chronic renal failure at the pre-dialysis stage].
Jungers PY; Nguyen-Khoa T; Joly D; Choukroun G; Massy ZA; Jungers P
Presse Med; 2003 Feb; 32(5):212-6. PubMed ID: 12610461
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
Krivoshiev S; Wizemann V; Czekalski S; Schiller A; Pljesa S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A;
Adv Ther; 2010 Feb; 27(2):105-17. PubMed ID: 20369312
[TBL] [Abstract][Full Text] [Related]
15. Impact of anemia treatment for left ventricular hypertrophy using long-acting erythropoietin-stimulating agents from the pre-dialysis to maintenance dialysis period in patients with chronic kidney disease, retrospective longitudinal cohort study.
Io H; Muto M; Sasaki Y; Ishizaka M; Kano T; Fukuzaki H; Maeda T; Shimizu Y; Nakata J; Suzuki Y
BMC Nephrol; 2023 Mar; 24(1):74. PubMed ID: 36966289
[TBL] [Abstract][Full Text] [Related]
16. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients.
Furuland H; Linde T; Ahlmén J; Christensson A; Strömbom U; Danielson BG
Nephrol Dial Transplant; 2003 Feb; 18(2):353-61. PubMed ID: 12543892
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis.
Parfrey PS; Lauve M; Latremouille-Viau D; Lefebvre P
Clin J Am Soc Nephrol; 2009 Apr; 4(4):755-62. PubMed ID: 19339417
[TBL] [Abstract][Full Text] [Related]
19. [Cardioprotective effect of erythropoietin preparations in patients with chronic renal failure].
Nikolaev AIu; Ermolenko VM; Milovanova LIu; Milovanov IuS
Ter Arkh; 2004; 76(9):40-3. PubMed ID: 15532375
[TBL] [Abstract][Full Text] [Related]
20. Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients.
Frank H; Heusser K; Höffken B; Huber P; Schmieder RE; Schobel HP
Kidney Int; 2004 Aug; 66(2):832-40. PubMed ID: 15253740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
